NCT07038369 - A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations | Biotech Hunter

Enrollment

134

Participants

Timeline

Start Date

July 29, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

January 31, 2029

Conditions

Advanced Solid TumorsBreast CancerBreast CarcinomaBreast NeoplasmsER Positive Breast CancerCervical CancersCervical NeoplasmsCervical CarcinomaTriple Negative Breast CancerGynecologic CancersGynecologic NeoplasmEndometrial CancerEndometrial NeoplasmEndometrial Carcinoma (EC)Fallopian CancerOvarian CarcinomaOvarian CancerOvarian NeoplasmsProstate CancersProstate CarcinomaSolid TumorsNeoplasmsNeoplasms by SiteBreast DiseasesUterine NeoplasmsGenital Neoplasms, FemaleUrogenital Neoplasms

Interventions

DRUG

ATV-1601

"Drug: ATV-1601~• Oral ATV-1601"

COMBINATION_PRODUCT

ATV-1601 + Fulvestrant

"Drug: ATV-1601~* Oral ATV-1601 Drug: Fulvestrant~* Intramuscular Injection"

Trial Locations (6)

32746

RECRUITING

Florida Cancer Specialists & Research Institute - Lake Mary, Lake Mary

63110

RECRUITING

Washington University, St Louis

77030

RECRUITING

MD Anderson Cancer Center, Houston

90033

RECRUITING

USC Norris Comprehensive Cancer Center, Los Angeles

97239

RECRUITING

Oregon Health & Science University, Portland

02114

RECRUITING

Massachusetts General Hospital, Boston